Hoffman M, Jenner P
Department of Pathology, University of North Carolina, Chapel Hill 27514.
Am J Clin Pathol. 1990 May;93(5):694-7. doi: 10.1093/ajcp/93.5.694.
Advances in the preparation of commercial Factor VIII concentrates have decreased the clinical use of cryoprecipitate to replace Factor VIII coagulant activity. Cryoprecipitate is now frequently transfused as a source of fibrinogen or von Willebrand factor (vWF). The minimum acceptable content of Factor VIII is prescribed, but no attempt is made to optimize, standardize, or assess the content of fibrinogen or vWF in cryo. If reasonably accurate information on the composition of cryoprecipitate were available, the physician could calculate an appropriate dose of cryo, thus avoiding unnecessary donor exposures and waste of product. This study was designed to measure the functionally active vWF and fibrinogen in cryoprecipitate prepared by three techniques in an attempt to optimize the yield of these hemostatically important components, and to obtain accurate information on the composition of the product. Cryoprecipitate was made from 82 units of fresh frozen plasma (FFP) as follows: (1) most of the supernatant plasma was expressed from "dry" cryo; (2) about 15 mL of plasma was left in each "regular" unit; and (3) "overnight" units were made from FFP thawed overnight in a refrigerator rather than in a 4 degrees C water bath as for the dry and regular units. Dry, regular, and overnight units had volumes of 8.8 +/- 1.5, 16.6 +/- 3.9, and 15.1 +/- 2.4 mL/bag, respectively. Dry cryoprecipitate units had significantly less fibrinogen and vWF than regular or overnight units. The vWF multimer pattern for all three types of cryoprecipitate was indistinguishable from that of normal pooled plasma. Thus, the amount of plasma expressed during preparation has a significant impact on the vWF and fibrinogen content of the resulting product. The amounts of these clinically important proteins should be assayed as a step toward rational determination of optimal cryoprecipitate doses in specific clinical settings.
商用凝血因子 VIII 浓缩物制备技术的进步已减少了冷沉淀在替代凝血因子 VIII 凝血活性方面的临床应用。如今,冷沉淀常作为纤维蛋白原或血管性血友病因子(vWF)的来源进行输注。虽然规定了凝血因子 VIII 的最低可接受含量,但并未尝试优化、标准化或评估冷沉淀中纤维蛋白原或 vWF 的含量。如果能获得关于冷沉淀成分的合理准确信息,医生就能计算出合适的冷沉淀剂量,从而避免不必要的供体暴露和产品浪费。本研究旨在测量通过三种技术制备的冷沉淀中功能性活性 vWF 和纤维蛋白原的含量,以优化这些对止血至关重要的成分的产量,并获取关于该产品成分的准确信息。冷沉淀由 82 单位新鲜冰冻血浆(FFP)制备而成,具体如下:(1)从“干式”冷沉淀中挤出大部分上清血浆;(2)每个“常规”单位中保留约 15 mL 血浆;(3)“过夜”单位由在冰箱中过夜解冻的 FFP 制成,而非像干式和常规单位那样在 4℃水浴中解冻。干式、常规和过夜单位每袋的体积分别为 8.8±1.5、16.6±3.9 和 15.1±2.4 mL。干式冷沉淀单位中的纤维蛋白原和 vWF 明显少于常规或过夜单位。所有三种类型冷沉淀的 vWF 多聚体模式与正常混合血浆的模式无法区分。因此,制备过程中挤出的血浆量对所得产品的 vWF 和纤维蛋白原含量有显著影响。应测定这些临床重要蛋白质的含量,作为在特定临床环境中合理确定最佳冷沉淀剂量的一个步骤。